Drugs / WJB001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06953323 | Jul 2025 → Jun 2029 expected | neoplasm | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05773820 | May 2023 → Aug 2026 overdue | cancer | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WJB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05773820 ↗ |
| Route | Oral | “WJB001 Capsules:160mg(or othe dosages),Oral,QD” NCT05773820 ↗ |